



**International Federation
of Pharmaceutical
Manufacturers & Associations**

STATEMENT

EB152 statement on prevention and control of non-communicable diseases and mental health

2 February 2023 – We support the draft decision on NCDs and mental health and the update of Appendix 3 to expand the scope of highly recommended interventions for NCD prevention and control. Under-resourced health systems and inadequate investment that is sufficient and sustainable in NCD prevention and control hamper the long-term ability to proactively address health crises. We welcome the WHO's continued work on NCDs and trust that NCDs will be a cornerstone of discussions at the 2nd High Level Meeting on UHC this year, alongside other treatable and preventable communicable diseases.

The industry remains a willing and critical partner in addressing gaps in NCD response. We maintain our commitment to tackling NCDs and will continue working with others to build access solutions and contribute toward stronger health systems, with the aim of improving the lives of people living with NCDs.

Chemin des Mines 9
1202 Geneva
Switzerland

+41 22 338 32 00
info@ifpma.org
ifpma.org

